Traynor Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Traynor Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.49M	Sell	9,049 -2,757	-23%	-$1.22M	0.21%	64
2026 Q1	$5.23M	Buy	11,806 +39	+0.3%	+$18.2K	0.31%	55
2025 Q4	$5.33M	Sell	11,767 -198	-2%	-$85.3K	0.28%	54
2025 Q3	$4.69M	Buy	11,965 +290	+2%	+$121K	0.27%	57
2025 Q2	$5.28M	Buy	11,675 +631	+6%	+$291K	0.37%	41
2025 Q1	$5.35M	Buy	11,044 +5,282	+92%	+$2.46M	0.45%	42
2024 Q4	$2.32M	Buy	5,762 +5,256	+1,039%	+$2.44M	0.16%	74
2024 Q3	$235K	Buy	+506	New	+$243K	0.01%	212

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Traynor Capital Management's VRTX Position: Q2 2026 in Review

Traynor Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 23% in Q2 2026, selling an estimated $1.22M and leaving 9,049 shares worth $4.49M. The position accounts for 0.21% of the portfolio, ranked #64.

Traynor Capital Management first reported a position in VRTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.35M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Traynor Capital Management held 9,049 shares of Vertex Pharmaceuticals worth $4.49M as of Q2 2026.
Traynor Capital Management sold 2,757 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.22M.
Vertex Pharmaceuticals made up 0.21% of Traynor Capital Management's portfolio in Q2 2026, its #64 holding.
Traynor Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Traynor Capital Management's Vertex Pharmaceuticals position peaked at $5.35M in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.